CARPROGESIC 50 MG TABLETS FOR DOGS.
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
18-12-2014
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
CARPROFEN
Available from:
Norbrook Laboratories Limited
ATC code:
QM01AE91
INN (International Name):
CARPROFEN
Dosage:
50 Milligram
Pharmaceutical form:
Tablets
Prescription type:
POM
Therapeutic group:
Canine
Therapeutic area:
Carprofen
Therapeutic indications:
N.S.A.I.D
Authorization status:
Authorised
Authorization date:
2006-12-08
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprogesic 50 mg Tablets for dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Carprofen
50 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablets:
A white/off white circular tablet with a break line on one face and “50” scored on the opposing face.
The tablets can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In the dog:
Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow
up to parenteral analgesia in the management of post operative pain.
4.3 CONTRAINDICATIONS
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in puppies less than 4 months of age.
Do not use in case of hypersensitivity to active substance or to any of the excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal
ulceration or bleeding, or where there is evidence of a blood dyscrasia.
Do not use in animals suffering from hemorrhagic syndrome.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to statements under Sections 4.3 and 4.5
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 03/12/2014_
_CRN 7019269_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS:
Use in aged dogs may involve additional risk.
If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as
Read the complete document
